Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06225804 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 14
- Study locations
NCT06225804 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 164 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 14 study locations across 14 states.
The verdict
NCT06225804, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 14
- Study locations
Study Summary
This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
Conditions Studied
Interventions
- DRUG ABSK112
Study Locations (14)
California
- Precision NextGen Oncology - Beverly Hills
Anhui
- Anhui Chest Hospital - Hefei
Fujian
- Fujian Cancer Hospital - Fuzhou
Harbin
- The first Affiliated Hospital of Xi'an Jiaotong University - Xi'an
Heilongjiang
- Harbin Medical University Cancer Hospital - Harbin
Henan
- Henan Cancer Hospital - Zhengzhou
Hubei
- Union Hospital Tongji Medical College Huzhong University of Science and Techology - Wuhan
Hunan
- Hunan Cancer Hospital - Changsha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2024-02-22 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06225804
The ClinicalTrials.gov registry entry for NCT06225804 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Abbisko Therapeutics Co, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ABSK112 is the first listed.
NCT06225804 reports 14 study locations spanning 14 distinct geographic areas - top geographies include California, Anhui, Fujian.
Frequently Asked Questions
What is clinical trial NCT06225804 about?
NCT06225804 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer". This is a first-in-human (FIH), multicenter, non-randomized, openlabel, phase 1 study of ABSK112 in patients with NSCLC to evaluate the safety, tolerability, PK, and preliminary antitumor efficacy.
What is the current status of trial NCT06225804?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2024-02-22. Estimated completion is 2028-03.
What conditions does trial NCT06225804 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06225804?
The interventions under investigation include: ABSK112 (DRUG).
Who is sponsoring clinical trial NCT06225804?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06225804 being conducted?
This trial has 14 study locations across California, Anhui, Fujian, Harbin, Heilongjiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.